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Abstract: The main purpose of this study was to evaluate liposomes containing a bile salt, 
sodium deoxycholate (SDC), as oral drug delivery systems to enhance the oral bioavailability 
of the poorly water-soluble and poorly permeable drug, cyclosporine A (CyA). Liposomes com-
posed of soybean phosphatidylcholine (SPC) and SDC were prepared by a thin-film dispersion 
method followed by homogenization. Several properties of the liposomes including particle 
size, polydispersity index, and entrapment efficiency were characterized. The in vitro release 
of CyA from these liposomes was less than 5% at 12 hours as measured by a dynamic dialysis 
method. The pharmacokinetic results in rats showed improved absorption of CyA in SPC/SDC 
liposomes, compared with CyA-loaded conventional SPC/cholesterol (Chol) liposomes and 
microemulsion-based Sandimmune Neoral®. The relative oral bioavailability of CyA-loaded 
SPC/SDC and SPC/Chol liposomes was 120.3% and 98.6%, respectively, with Sandimmun 
Neoral as the reference. The enhanced bioavailability of CyA was probably due to facilitated 
absorption by the liposomes containing SDC rather than improved release rate.
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Introduction
Cyclosporine A (CyA) is a lipophilic cyclic polypeptide composed of 11 amino acids, 
and has been utilized clinically as a potent immunosuppressant to prevent allograft 
rejection in various organ transplantations and to treat systemic and local autoimmune 
disorders.1 Despite the great therapeutic interest of CyA, its original oil-based oral 
formulation (Sandimmune®) shows high intra- and inter-patient variability and poor 
bioavailability due to its high molecular weight, rigid cyclic structure, and poor water-
solubility.2–4 P-glycoprotein mediated efflux from the enterocytes and extensive pre-
systemic metabolism in the gut wall and liver further reduces CyA oral bioavailability.5 
The current clinically available commercial product of CyA is a microemulsion-based 
pre-concentrate formulation (Sandiummune Neoral®), which shows relatively high 
therapeutic oral bioavailability with reduced variability. In spite of the success of 
Neoral, CyA attracts continuous attention in the field of oral delivery mainly because 
it has extremely poor water solubility and poor permeability, and represents one of the 
most challenging model drugs to test the efficiency of oral delivery systems.6,7
In the past decade, various nanoscale drug delivery systems have been investi-
gated to increase the oral bioavailability of CyA.6–10 Among these vehicles, liposomes 
show promising potential due to their absorption-enhancing capability and excellent 
biocompatibility. The conventional liposome formulation composed of phosphatidyl-
choline and cholesterol showed oral bioavailability similar to Sandimmune Neoral.6 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  Nevertheless, there are problems associated with orally 
administered liposomes when they are exposed to the harsh 
environment in the gastrointestinal tract. The pH gradient, 
pancreatic lipases, and the bile salts can lead to destabiliza-
tion of the liposomal vesicles,11 among which the key role of 
the bile salts is the most significant.12 In view of this, efforts 
have been made to improve the stability of conventional lipo-
somes for oral delivery, including polymeric coating13,14 and 
encapsulating liposomes into bulk vehicles.15,16 In addition, 
studies revealed that incorporation of bile salts in the lipid 
bilayers could stabilize the membrane against the detrimen-
tal effects of physiological bile acids in the gastrointestinal 
(GI) tract.17,18 Bile salts stabilized vesicles (bilosomes) have 
shown promising potential in oral vaccine delivery.17,19,20 
Bilosomes could provide both protection to the antigen from 
the hostile environment of GI tract as well as enable trans-
mucosal uptake and subsequent immunization.19 Thus, it was 
indicated that liposomes containing bile salts may act as more 
stable carriers than conventional liposomes and facilitate the 
  transmembrane transport and absorption of drugs.
In our previous study, liposomes containing a bile salt, 
sodium deoxycholate, were confirmed to enhance the oral 
  bioavailability of a poorly water-soluble drug fenofibrate by 
5.13-fold,21 which could be interpreted by multiple mecha-
nisms of facilitated solubilization12,22 and facilitated absorption 
through the M-cell uptake pathway.23 However, a 4.4-fold 
increase in oral bioavailability of the same drug can be observed 
for fast-dissolving solid dispersion   formulation.24 It seemed 
that improving dissolution of the poorly water-soluble drugs 
like fenofibrate, which are classified as BCS II drugs accord-
ing to the biopharmaceutics classification system,25 was a 
very efficient way of enhancing the oral bioavailability. The 
superiority of liposomes containing bile salts has not been 
confirmed in the previous study using a BCS II model drug. 
Therefore, we sought to confirm the enhancing effect of this 
new oral drug carrier, using more challenging BCS IV drugs 
such as CyA, whose bioavailability cannot be simply enhanced 
by solubilization mechanisms.26 In this study, CyA-loaded 
liposomes containing a bile salt, sodium deoxycholate, were 
prepared and evaluated both in vitro and in vivo with the aim 
to enhance the oral bioavailability of CyA.
Materials and methods
Materials
Cyclosporine A (CyA) was purchased from the   Pharmaceutical 
Factory of Sichuan Institute of Antibiotic Industries 
(Chengdu, China). Soybean phosphatidylcholine (SPC) was 
supplied by Lipoid (Germany). Sodium deoxycholate (SDC) 
was purchased from Sinopharm Chemical Reagent Co. 
Ltd (Shanghai, China). Cholesterol (Chol) was obtained 
from Shanghai Toshisun Enterprise Co. Ltd (Shanghai, 
China). Sephadex G-50 was purchased from Pharmacia 
(Uppsala, Sweden). Ultrapure water was prepared by a 
Milli-Q purification system (Millipore, Molsheim, France). 
High performance liquid chromatograpy (HPLC)-grade ace-
tonitrile and tert-butyl methyl ether was supplied by TEDIA 
(Fairfield, USA). Sandimmune Neoral, a microemulsion-
based CyA soft capsule (25 mg) (Novartis Pharma GmbH, 
Germany) was purchased from a local distributor. All other 
chemicals were of analytical grade and used as received.
Preparation of liposomes containing 
sodium deoxycholate
SPC/SDC liposomes were prepared by an improved thin-film 
dispersion method.21,27 In brief, SPC, SDC, and CyA were 
dissolved in dichloromethane/methanol (9/1, v/v) in a round-
bottom flask. Then the organic solvent was removed using a 
rotary evaporator (RV 10 digital, IKA Works, German) in a 
30°C water bath (HB 10 digital, IKA Works, German) under 
vacuum. The dried lipid films were maintained under reduced 
pressure for 2 hours to remove traces of the solvent. The 
lipid film was then hydrated with phosphate buffer (50 mM, 
pH 7.4) for 30 minutes at 40°C to obtain a crude dispersion of 
the liposomes. The liposome dispersion was further homog-
enized by passing through a high-pressure homogenizer 
(Avestin Em-C3, Ottawa, Canada) to obtain an opalescent 
fine   dispersion. The liposome dispersion was stored at 4°C 
until use. For the preparation of SPC/Chol liposomes, similar 
procedures were followed using Chol in lieu of SDC.
Particle size and zeta potential 
measurement
The particle size of the prepared CyA-loaded liposomes was 
determined by the dynamic light scattering method using 
NICOMP™ 380 ZLS Zeta Potential/Particle Sizer (NICOMP 
Particle Sizing Systems, Santa Barbara, CA). Raw data were 
collected over 5 minutes at 23°C and at an angle of 90°, which 
were further processed with the ZPW388 software program. 
The particle size was expressed with volume-weighted 
Gaussian distribution (with Chi-squared value ,3).28 The 
zeta potential of liposomes was also measured using the 
same equipment.
Entrapment efficiency
The entrapment efficiency of CyA in the liposomes was 
determined by a gel permeation chromatography method.6 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Briefly, the Sephadex G-50 gel-filled column (20 cm × 1.0 cm) 
was first eluted with 100 µL blank liposomes to saturate 
the   column and improve the column recovery. Subse-
quently, CyA-loaded SPC/SDC or SPC/Chol liposomes 
were mounted and eluted with phosphate buffer (pH 7.4) 
at a flow rate of 0.5 mL/minute to separate free CyA from 
liposomes. The elution was monitored through turbid-
ity measurement at a wavelength of 500 nm by using a 
UV-2401spectrophotometer (Shimadzu, Japan). The eluent-
containing liposomes were dissolved with methanol and 
analyzed for CyA. The   entrapment efficiency (EE%) was 
calculated as:
  EE% = Wc/Wt × 100%
where Wc and Wt denoted the weight of CyA in liposomes 
and total CyA weight in the liposome dispersion.
Determination of cyA by hPLc
In this study, CyA in the formulations and release 
media was determined by an HPLC/UV method.29 The 
LC-10 ATvp HPLC system (Shimadzu, Japan) was com-
posed of a binary pump, a tunable ultraviolet detector, a 
column heater, and a manual injector. The mobile phase 
was a mixture of acetonitrile/water/tert-butyl methyl ether/
phosphoric acid (60/35/5/0.1, v/v/v/v), pumped at a flow 
rate of 1.5 mL/minute. CyA was separated using a C18 
column (Venusil XBP, 5 µm, 4.6 mm × 150 mm; Agela, 
Tianjin, China) guarded with a refillable precolumn (C18, 
2.0 mm × 20 mm; Alltech, Lexington, USA) and a stain-
less pre-heating tube (internal diameter: 0.25 mm; length: 
1000 mm). The detection wavelength and column tempera-
ture were set to 226 nm and 70°C, respectively. The linearity 
range of the calibration curve was within 0.515–51.5 µg/mL 
with a correlation   coefficient of 0.9999.
Transmission electron microscopy
The morphology of CyA-loaded SPC/SDC liposomes was 
observed under a high-resolution transmission electron 
microscopy (TEM) (Tecnai G2 F20, FEI, Holland) with 
a field-emission gun operating at 200 kV after negative 
  staining. Briefly, liposomes were diluted with phosphate 
buffer and adsorbed onto a copper grid and air-dried for 
1 minute at room temperature after removing the excessive 
sample with filter paper. A drop of 2% phosphotungstic acid 
(w/v, pH 6.5 in distilled water) was then added and the lipo-
somes were stained for 30 seconds. At the end, the sample 
was air-dried for another 10 minutes at room temperature 
before TEM observation.
In vitro release study
In vitro release of CyA from SPC/SDC, SPC/Chol liposomes 
and Neoral was evaluated by a dynamic dialysis method29 
in a ZRS-8G release tester (Tianjin, China) according to the 
Chinese Pharmacopoeia Method III (the small beaker method). 
The fundamental properties of both SPC/SDC and SPC/Chol 
liposomes are given in Table 1. Before release test, 3 mL of 
SPC/SDC and SPC/Chol liposome dispersion were sealed in 
dialysis bags (MWCO 14,000, Millipore, Boston, PA), whereas 
Neoral capsules were dispersed in 12.5 mL ultrapure water, 
3 mL of which was sealed in dialysis bags. Then the dialysis 
bags were immersed in 100 mL release medium containing 
0.2% (w/v) sodium lauryl sulfate thermostatically maintained 
at 37 ± 0.5°C and stirred at a rotating speed of 100 rpm. At time 
intervals of 0.5, 1, 1.5, 2, 3, 4, 6, 10, and 12 hours, 0.2 mL of 
release sample was withdrawn and centrifuged at 10,000 rpm 
for 10 minutes at 25°C. The CyA content was then determined 
by HPLC as described above.
sample preparation and determination  
of cyA in rat whole blood
CyA in rat whole blood was determined using the HPLC-UV 
method as described above with modifications. The same 
LC-10 ATvp HPLC system and Venusil XBP C18 column 
with guard column and pre-heating assemblies were used as 
described above, except that the volume ratio of the mobile 
phase acetonitrile/water/tert-butyl methyl ether/phosphoric 
acid was changed to 525/425/50/1 (v/v/v/v), and the detection 
wavelength was set to 210 nm.
To prepare the rat blood samples, CyA was extracted by 
the reported liquid–liquid extraction procedures with minor 
Table 1 Formulation details of sPc/sDc and sPc/chol liposomes for in vitro release and in vivo bioavailability studies (n = 3)
Liposome 
type
SPC/SDC 
(Chol) ratio
Theoretical SPC 
concentration 
(%, w/v)
Theoretical 
CyA loading 
(mg/mL)
Particle 
size (nm)
Polydispersity Zeta potential 
(mV)
Entrapment 
efficiency (%)
sPc/sDc 3/1 5 2 85.6 ± 1.0 0.064 ± 0.013 -35.25 ± 4.42 94.05 ± 2.76
sPc/chol 5/1 5 2 98.1 ± 2.3 0.117 ± 0.032 -32.09 ± 3.82 95.22 ± 3.02
Abbreviations: chol, cholesterol; cyA, cyclosporine A; sPc, soybean phosphatidylcholine; sDc, sodium deoxycholate.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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modification.28 To 300 µL rat blood, add 15 mg of sodium 
fluoride followed by 40 µL of internal standard solution 
(cyclosporine D, 20 µg/mL in methanol). After vortex mix-
ing for 30 seconds, 750 µL diethyl ether anhydrous was 
added and vortex mixed for 7 minutes. After centrifuging 
at 12,000 rpm for 10 minutes at 4°C, the organic layer was 
transferred to another tube and evaporated under a light 
stream of nitrogen at 37°C. The residue was reconstituted 
using 40 µL methanol/0.05 mol/L hydrochloric acid solu-
tion (6/4, v/v). After washing the injection solution with 
150 µL n-hexane for 2.5 minutes, and a brief centrifugation 
at 12000 rpm for 10 minutes at 4°C, 20 µL of the solution 
was injected for HPLC analysis. Quantification was based 
on the peak area ratio R (ACyA/ACyD). Linearity was observed 
over the concentration range of 0.147–14.7 µg/mL with cor-
relation coefficients of over 0.99 (a typical calibration curve: 
R = 0.4036C - 0.0423, r2 = 0.9983, n = 7). The lower limit 
of quantification for the determination of CyA in rat blood 
was found to be 0.07 µg/mL. Accuracy for the determination 
of CyA in rat blood (n = 9) was 93.24% ± 4.16%. Intra-day 
and inter-day precisions were all below 7% and the extraction 
recovery of CyA in rat blood (n = 9) was 73.25% ± 5.17%.
Bioavailability study
The pharmacokinetics of the CyA-loaded SPC/SDC lipo-
somes (Table 1) were compared with those of CyA-loaded 
SPC/Chol liposomes and Neoral capsules (25 mg/capsule, 
Sandimmune Neoral) in rats after an oral dose of 15 mg/kg. 
Male Wistar rats, weighing 280 ± 20 g, were supplied by the 
Laboratory Animal Service Center of Fudan University. The 
rats were housed in an air-conditioned room with controlled 
temperature (24 ± 1°C) and humidity (55% ± 5%) and free 
access to water, and maintained on a 12 hours dark/light 
cycle. The experiment adhered to the Guidelines of the 
Ethical Committee of Fudan University on use of experi-
mental animals and followed the principles outlined in the 
Declaration of Helsinki for all human or animal experimental 
investigations. All the animals used in the study were fasted 
overnight before dosing. Animals were randomly assigned 
into 3 groups with 6 animals in each group. The liposome 
formulations were administered directly by gavage using 
18-gauge oral feeding needle, while the content of Neoral 
capsules was administrated similarly, but after diluting with 
10 mL ultra pure water per capsule. After administration, 
about 350 µL of the blood was collected through the tail vein 
into heparinized tubes at time intervals of 0.5, 1.0, 1.5, 2.0, 
2.5, 3.0, 4.0, 6.0, 8.0, 12.0, and 24.0 hours. Blood samples 
were stored at -20°C until analysis.
Pharmacokinetic analysis was performed by a 
  model-independent method, using the DAS 2.1.1 computer 
program (issued by the State Food and Drug Administration 
of China for pharmacokinetic study). Cmax and Tmax were 
observed as raw data. Area under the curve to the last mea-
surable concentration (AUC0-t was calculated by the linear 
trapezoidal rule. Area under the curve extrapolated to infinity 
(AUC0-∞) was calculated as AUC0-t + Ct/k, where Ct and k 
were the last measurable concentration and the elimination 
constant, respectively.
statistical analysis
Raw data were analyzed using SPSS statistical software 
(version 11.0, SPSS, Inc.). Post hoc multiple comparisons 
were done using one-way ANOVA. The difference between 
groups was considered statistically significant with a P value 
less than 0.05.
Results and discussion
Preparation and characterization  
of sPc/sDc liposomes
Liposomes containing sodium deoxycholate can be prepared 
successfully by a thin-film dispersion/homogenization 
method with a wide range of particle size and entrapment 
efficiency. Although we previously reported similar lipo-
somes encapsulating another poorly water-soluble drug 
fenofibrate,21 our preparation was modified when encap-
sulating CyA in this study. Specifically, we used a dichlo-
romethane/methanol mixture solvent rather than diethyl 
ether anhydrous in order to dissolve SPC, SDC, and CyA 
simultaneously because SDC is freely soluble in methanol, 
but not in dichloromethane or diethyl ether anhydrous. On 
the other hand, we used phosphate buffer (50 mM, pH 7.4) 
in this study rather than SDC solution as hydration medium 
in order to avoid possible formation of micelles or vesicles 
by cholate itself during hydration.
Since particle size exerts significant influence on the 
performance of liposomes both in vitro and in vivo,30 we 
first studied the effects of several factors on the particle size 
and distribution. As shown in Figure 1A and 1C, SPC/SDC 
liposomes before homogenization was typically 1 micron in 
size and exhibited wide size distribution. The particle size 
and polydispersity index (PI) was dramatically reduced after 
homogenization, and the lowest diameter (around 80 nm) 
of liposomes could be achieved when the homogenization 
pressure increased to 100 bar (Figure 1B, 1C). Although the 
particle size dropped dramatically, there was no worry about 
phasing-out of CyA. Due to its lipophilic nature and high International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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affinity with the lipid bilayer, CyA would readily associate 
with the lipid and maintain a “solubilized” state. Both the 
TEM observation and entrapment efficiency measurement 
shown below confirmed the itnegrity of the liposomal 
  structure. However, the particle size and PI were signifi-
cantly increased (P , 0.01) when we further increased the 
homogenization pressure to 200 bar. Rupture and aggregation 
of the vesicle under large shearing force of homogenization 
could be employed to interpret this phenomenon. In addition, 
no significant variation in particle size could be observed at 
homogenization cycles of more than 5 and the homogeniza-
tion pressure at 100 bar (P . 0.05) (Figure 1D). Nevertheless, 
the lowest PI could be achieved when we increase the cycles 
of homogenization to 20, and rupture and aggregation might 
occur after 25 times of homogenization, which resulted in 
increased PI (Figure 1D). Thus we chose a homogeniza-
tion pressure of either 100 bar or 200 bar to prepare SPC/
SDC liposomes for the following investigation. We chose 
300 bar and 20 cycles to homogenize SPC/Chol liposomes, 
however, which were less flexible, so as to obtain similar 
mean particle size as SPC/SDC liposomes. Moreover, the 
micron-scale liposomes might have a multilamellar structure 
that is common for liposomes produced by the thin-film dis-
persion method. Further homogenization possibly produced 
unilamellar liposomes due to the typically small particle size 
of less than 100 nm.31 Although energy input increased with 
the increase of homogenization pressure and the number of 
homogenization cycles, the particle size could not be reduced 
further because of the significantly increased surface tension. 
Further reduction in particle size may possibly be achieved 
through monitoring the composition of the lipids. We did not 
use extremely small sized particles, which would not favor 
uptake by the intestinal lymphatic system.32
The ratio of SPC/SDC, concentration of SPC and CyA 
loading also had significant influence on particle size and 
distribution. A substantial increase in particle size corre-
lated with decrease of SDC in the bilayer with about 80 nm 
particle size and PI of 0.1 at a SPC/SDC ratio of 3/1, and 
there was no significant difference until we increased the 
SPC/SDC ratio to 4/1 (P . 0.05) (Figure 2A). In contrast, 
particle size and PI markedly increased when the SPC/
SDC ratio was further increased to 6/1 or 9/1 (Figure 2A). 
The reduction in particle size and PI as a function of SDC 
content in lipid bilayers might be attributable to increased 
flexibility and reduced surface tension of the vesicles.21 
Our findings were similar to the results obtained by 
  Chingunpitak et al,33 namely, that an increase in weight ratio 
of SDC would reduce the particle size of the   suspension 
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obtained from binary ground mixtures of DHA/SDC. The 
effect of SPC concentration on particle size and PI was 
investigated further, and the results showed that the particle 
size and PI were not significantly influenced by increasing 
the weight ratio of SPC to 4% (P . 0.05)   (Figure 2B). The 
liposomes were slightly enlarged, however, with increased 
PI when the weight ratio of SPC reached 6%, which was 
possibly due to increased viscosity because of the higher 
concentration of SPC (Figure 2B). The drug loading had no 
significant effects (P . 0.05) on particle size and PI when 
the concentration of CyA was below 2 mg/mL. Particle 
size and PI were dramatically increased at CyA loading 
of 2.4 mg/mL, however (Figure 2C). Although the exact 
mechanisms still need further elucidation, possible interpre-
tation includes recrystallization of non-encapsulated drug 
and significantly increased surface tension.
Figure 3 shows the effect of SPC/SDC ratio, the concen-
tration of SPC and CyA loading on the entrapment efficiency 
of CyA into SPC/SDC liposomes. Being highly lipophilic, 
CyA could be easily encapsulated in the liposomes with 
high entrapment efficiency as reported in a previous study.6 
  However, the results still indicated that the entrapment 
efficiency of CyA was slightly reduced with decreased 
  content of SDC in the liposomal bilayers (Figure 3A). 
Similar results were also reported by Sun et al34 showing 
that SDC could improve the entrapment efficiency of hex-
amethylmelamine, a   lipophilic drug, although this process 
was phosphatidylcholine-  dependent. It was also reported that 
SDC, with surface-active properties, can incorporate perpen-
dicularly into the surface of the bilayer membrane, perturbate 
the acyl chains of the lipid matrix, increase the flexibility of 
the membrane, and thereby improve the solubility of highly 
lipophilic drug in the membrane.35 When the ratio of SPC/
SDC was greater than 4/1, however, the change in entrapment 
efficiency was not significant, suggesting that the capacity 
of solubilization by SDC was limited, a result similar to that 
reported by Sun et al.34 A significant increase in entrapment 
efficiency was observed with the increase of SPC content at 
the weight ratio of 3% (Figure 3B), which may be attributable 
to the fact that higher lipid content offers more lipophilic 
space for CyA. When the lipid content was increased fur-
ther from 3% to 6%, however, the amount of CyA loading 
in liposomes showed no marked change. Further experi-
ments showed that entrapment efficiency was not affected 
by drug loading when the drug concentration was below 
2 mg/mL, whereas the entrapment efficiency   significantly International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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decreased when CyA was increased to 2.4 mg/mL (P , 0.01) 
 ( Figure 3C). This observation was inconsistent with our 
assumption that there was possible phasing out of nonencap-
sulated CyA as observed for dramatically increased particle 
size and PI at CyA 2.4 mg/mL (Figure 2C). Further evidence 
of white precipitation at CyA loading up to 2.4 mg/mL in 
liposomes after a brief centrifugation at 5000 rpm for 10 min 
at 25°C confirmed our assumption.
The results of zeta potential measurements are shown in 
Table 1. There was no significant different between SPC/SDC 
and SPC/Chol liposomes (P . 0.05). It was reported that 
bilosomes exhibited more stability than conventional vesicles 
in the GI tract17 which, however, cannot be interpreted by 
zeta potential-based stabilization mechanism. The possible 
reason for increased stability of bilosome in the GI tract could 
be attributed to the defending ability of liposomes contain-
ing bile salt against the destructive effect of physiological 
surfactants.18 Furthermore, a short-term stability study of 
1 week was carried out to insure the quality of the formula-
tion before oral administration. The entrapment efficiency, 
particle size, and zeta potential of the SPC/SDC liposomes 
were determined at 0, 1, 4, and 7 days after storage at room 
temperature. As shown in Table 2, the characteristics of the 
SPC/SDC liposomes changed significantly.
Transmission electron microscopy
Figure 4 shows the TEM photograph of CyA-loaded SPC/SDC 
liposomes. The spherical vesicular structure could be easily 
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Figure 3 Effect of formulation variables on the entrapment efficiency of CyA-loaded SPC/SDC liposomes. SPC/Chol (A) (*P , 0.05 comparing sPc/chol ratio 3/1 and 4/1); 
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Table 2 The stability of sPc/sDc liposomes for 7 days stored in 4°c (n = 3)
Time (days) Entrapment efficiency (%) Particle size (nm) Polydispersity Zeta potential (mV)
0 93.27 ± 3.85 87.2 ± 2.1 0.074 ± 0.015 -33.05 ± 2.79
1 94.72 ± 2.41 85.3 ± 1.9 0.071 ± 0.009 -35.22 ± 3.42
4 92.53 ± 3.21 88.9 ± 2.0 0.080 ± 0.019 -33.56 ± 3.75
7 90.38 ± 4.33 90.2 ± 3.4 0.085 ± 0.013 -30.45 ± 3.69
Abbreviations: sPc, soybean phosphatidylcholine; sDc, sodium deoxycholate.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 4 TeM morphology of cyA-loaded sPc/sDc liposomes.
Abbreviations:  cyA,  cyclosporine  A;  sPc,  soybean  phosphatidylcholine;  sDc, 
sodium deoxycholate.
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identified, which was similar to a previous report of fenofibrate-
loaded liposomes.21 The particle size of CyA-loaded SPC/SDC 
liposomes was about 90 nm, which was in good correlation with 
results obtained by particle size measurement.
In vitro release
Figure 5 shows the in vitro release profiles of the three CyA 
formulations. The overall release of CyA from CyA-loaded 
SPC/Chol, SPC/SDC liposomes, and Neoral appeared to 
be very slow with no more than 5% at 12 hours. Since 
the solubility of CyA in 0.2% SDS solution was about 
0.921 mg/mL,29 good sink conditions could be maintained 
throughout the release test. CyA in solution could diffuse 
completely across the dialysis bag within 1 hour, indicating a 
negligible hindering effect of the dialysis bag on CyA release. 
Thus the possible reason for slow CyA release from the three 
formulations was ascribed to the high affinity of CyA with 
the hydrophobic materials in the formulations.29
Pharmacokinetics and oral bioavailability
To investigate the role of bile salt in enhancing oral absorp-
tion of CyA, oral bioavailability of CyA-loaded SPC/SDC 
liposomes in rats was compared with those of SPC/Chol lipo-
somes and Neoral. The mean whole blood CyA concentra-
tion versus time plots of three CyA formulations are shown 
in Figure 6 and the pharmacokinetic parameters obtained by 
the statistical moment method are shown in Table 3.
After gavage administration, the Tmax of Neoral was 
2.67 ± 0.69 hours, which was similar to results reported by 
Wang et al.36 There was no significant difference between the 
SPC/Chol liposomes and Neoral (P . 0.05). However, the 
Tmax of SPC/SDC liposomes (4.67 ± 1.49 hours) appeared to be 
significantly longer than that of both the SPC/Chol liposomes 
and Neoral (P , 0.01). The Cmax of the SPC/SDC liposomes, 
Neoral, and SPC/Chol liposomes was 2.65 ± 0.70 µg/mL, 
2.57 ± 0.20 µg/mL, and 2.28 ± 0.31 µg/mL, respectively, and 
no significant difference was observed between each of the 
three formulations (P . 0.05). There was also no significant 
difference in the maximum retention time (MRT) values 
between either two of the three formulations (P . 0.05). SPC/
SDC liposomes showed significantly higher AUC0–t value 
(42.16 ± 6.30 µg ⋅ h/mL) than either the SPC/Chol liposomes 
(34.56 ± 4.08 µg ⋅ h/mL) or Neoral (35.02 ± 4.68 µg⋅h/mL) International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Dovepress
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Table 3 Pharmacokinetic parameters after oral administration of cyA-loaded sPc/sDc, sPc/chol liposomes and sandimmune 
Neoral (n = 6)
Formulation Tmax (h) Cmax (μg/mL) t1/2 (h) AUC0–t 
(μg ⋅ h/mL)
AUC0-∞ 
(μg ⋅ h/mL)
MRT (h) Relative 
bioavailability*
sPc/sDc liposomes 4.67 ± 1.49 2.65 ± 0.70 20.54 ± 7.63 42.16 ± 6.30 73.90 ± 6.63 10.73 ± 0.90 120.3%
sPc/chol liposomes 2.67 ± 0.69 2.28 ± 0.31 19.84 ± 6.50 34.56 ± 4.08 60.49 ± 10.79 10.42 ± 0.37 98.6%
sandimmun Neoral® 2.67 ± 0.69 2.57 ± 0.20 19.09 ± 10.15 35.02 ± 4.68 65.41 ± 29.55 10.23 ± 0.64
Note: *relative bioavailability (%) of the liposomes calculated on AUc0-t with sandimmune Neoral as the reference.
Abbreviations: chol, cholesterol; cyA, cyclosporine A; soybean phosphatidylcholine; sDc, sodium deoxycholate; MrT, maximum retention time.
(P , 0.05). The relative bioavailability, which was calculated 
on AUC0–t, of the SPC/SDC and SPC/Chol liposomes was 
120.3% and 98.6%, respectively, compared with Neoral. The 
results indicated that conventional liposomes showed similar 
pharmacokinetic profiles to Neoral, which was in accordance 
with the results by Guo et al,6 whereas SPC/SDC liposomes 
showed significantly enhanced oral absorption.
In our previous study on fenofibrate-loaded SPC/SDC 
liposomes, several mechanisms were proposed to interpret the 
enhanced oral bioavailability of fenofibrate.21 It seems that both 
enhanced solubilization (facilitated transition from liposomal 
vesicles to mixed micelles) and enhanced uptake of liposomes 
as integral vesicles through the M-cell pathway are potential 
mechanisms. However, the enhanced   solubilization mechanism 
might not function because CyA could not   easily permeate 
across the intestinal epithelia as single CyA   molecules. There-
fore, the potential explanation for enhanced oral bioavailability 
of CyA by lipid-based vehicles was that the intact liposomal 
vesicles may promote the uptake by M-cells in the Peyer’s 
patches and increase the absorption through the lymphatic path-
way. Our current study extended the previous investigation6 to 
reveal that SPC/SDC liposomes further enhanced oral bioavail-
ability of CyA compared with that of SPC/Chol liposomes and 
Neoral. Several mechanisms may contribute to the superiority 
of SPC/SDC liposomes over conventional liposomes. On one 
hand, incorporation of bile salts in lipid vesicles could stabilize 
the membrane against the detrimental effects of physiological 
bile acids in the GI tract,17 resulting in more stable SPC/SDC 
liposomes than SPC/Chol liposomes. The stabilizing effect 
might extend the resident time of SPC/SDC liposomes in the GI 
tract, resulting in longer Tmax compared with that of SPC/Chol 
liposomes or Neoral. It was assumed that more intact liposomes 
would be available for uptake by the M-cell pathway. On the 
other hand, permeation of intact liposomes through the intestinal 
epithelia pathway was another potential mechanism. Owing 
to the penetration-enhancing effect of sodium deoxycholate, 
enhanced permeation of liposomes containing SDC across the 
Caco-2 cell monolayer has been observed.37 However, these 
mechanisms need further elucidation in vivo.
Conclusion
Liposomes containing SDC could be prepared in high SDC 
content with SPC/SDC ratio of 3/1 by a thin film dispersion 
method followed by homogenization. The entrapment effi-
ciency of CyA was as high as 95% with little escape of CyA 
during the preparation process. The particle size could be easily 
tailored by adjusting the homogenization pressure and the num-
ber of homogenization cycles. The pharmacokinetic results 
revealed that liposomes containing sodium deoxycholate were 
superior to the microemulsion-based formulation (Sandium-
mune Neoral) and conventional liposomes, in improving the 
oral bioavailability of CyA. Comparison between SPC/SDC 
and SPC/Chol liposomes highlights the desirable effect of the 
bile salt SDC on the oral bioavailability of poor water-soluble 
and poorly permeable drugs. A mechanism of enhanced solubi-
lization could be excluded owing to the fact of limited release 
of CyA from either the liposomal or the microemulsion-based 
formulations. Being absorbed as intact vesicles seems to be a 
possible   interpretation to the enhanced oral bioavailability.
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